|
|
|
| The Efficacy of Aspirin in the Treatment of Primary Hypertension with CHD and its Effect on Plasma Viscosity and Platelet Aggregation Rate |
| CUI Linlin, GAO Guojie, HU Taohong |
| The General Hospital of Rocket Army, Beijing 100088, China |
|
|
|
|
Abstract Objective: To observe the curative efficiency of aspirin on primary hypertension combined with coronary heart disease(CHD) and its influence on plasma viscosity and platelet aggregation rate. Methods: A total of 107 cases of primary hypertension patients with coronary heart disease were randomly divided into two groups by the random number table method: the study group (56 cases) and the control group (51 cases). The control group were given Telmisartan (40mg/d), Isosorbide Dinitrate tablets (30mg once, 3 times per day), while the study group were given aspirin (100mg/d) on the basis of the control group. Compare the blood pressure, blood lipid levels, left ventricular ejection fraction (LVEF), plasma viscosity and platelet aggregation rate changes of the two groups before and after 6 months' treatment. Results: After 6 months' treatment, the level of blood pressure, TC, TG, plasma viscosity and platelet aggregation rate of both groups were all declined on different degree, while the level of plasma viscosity and platelet aggregation rate of the study group were more significant lower than that of the control group (P<0.05). In addition, the LVEF of both groups were all increased significantly (P<0.01), and the LVEF level of the study group were significantly higher than the control group (P<0.05); the total effective rate of the study group were significantly higher than the control group (90.9% vs 76.5%, P<0.05). Conclusion: The therapy of aspirin can improve the blood viscosity and LVEF level for primary hypertension patients with CHD, and improve the curative efficiency as well.
|
|
|
|
|
|
[1] 中国高血压防治指南修订委员会.中国高血压防治指南[J].中华高血压杂志,2011,19(8):701~743.
[2] 李进峰,段慧莲,朱娜,等.替米沙坦治疗老年轻中度高血压的临床观察[J].中华高血压杂志,2005,13(9):578~579.
[3] 吕红霞.替米沙坦治疗高血压临床观察[J].中国慢性病预防与控制,2007,15(5):454~455.
[4] 颜红兵.临床冠心病诊断与治疗指南[M].北京:人民卫生出版社,2010.
[5] Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC practice guidelines for the management of arterial hypertension[J].Blood Press,2014,23(1):3~16.
[6] 陈娟娟.单硝酸异山梨酯片治疗冠心病心绞痛的临床疗效观察[J].北方药学,2011,8(7):21.
[7] 丛玉隆,张岩,殷宗健,等.不同剂量阿司匹林抑制血小板聚集功能时效探讨[J].中华医学检验杂志,1998,21(3):263~265.
[8] 中国老年高血压治疗共识专家委员会.中国老年高血压治疗专家共识[J].中华老年心脑血管病杂志,2008,10(9):641~649.
[9] 刘伟佳,陈维清,罗不凡,等.广州市15岁及以上居民高血压流行特征及防治现状[J].中国慢性病预防与控制,2007,15(2):110~112.
[10] 程婧,何非,王丽姿,等.老年高血压患者达标率与知识行为依从性及生活方式的相关性研究[J].中华护理杂志,2011,46(2):117~120.
[11] 王勇,范书英.三大高血压指南精要对比解读[J].中国全科医学,2012,15(4B):1184~1188.
[12] 王云,柯元南,钱端,等.替米沙坦治疗原发性高血压的疗效和安全性[J].中日友好医院学报,2002,16(5):283~285.
[13] 李庆辉,杨天伦,谭碧峰,等.替米沙坦对高血压患者左室肥厚及C反应蛋白的影响[J].中华全科医学,2010,8(5):554~556.
[14] 龚武田,李家富.替米沙坦对高血压患者左心室重构及血浆B型钠尿肽的影响[J].西南军医,2010,12(3):452~454.
[15] 朱旭婷,王长谦,朱福.替米沙坦对老年代谢综合征患者血管内皮功能的影响[J].老年医学与保健,2010,16(4):248~250.
[16] 高学东,胡科,魏虎.单硝酸异山梨酯片治疗老年性高血压的对照研究[J].中外健康文摘,2011,8(48):53~54.
[17] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会.阿司匹林在动脉硬化性心血管疾病中的临床应用:中国专家共识(2005)[J].中华心血管病杂志,2006,34(3):281~284.[18] Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients[J].BMJ,2002,324(7329):71~86.
[19] Baigent C,Blackwell L,Collins R,et al.Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials[J].Lancet,2009,373(9678):1849~1860.
[20] 郭新胜,施海明,罗心平,等.不同剂量阿司匹林对冠心病患者血小板聚集功能的影响[J].现代诊断与治疗,2002,13(2):105~106. |
|
|
|
2018, Vol. 24 
